Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthRX vs PauseRX

HealthRX
Graded #8

Higher grade

vs+17.599999999999994
PauseRX
Graded #147

Lower grade

The verdict

HealthRX takes it — 86.1/100 to 68.5/100.

HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHealthRX +19
85
66
Dose & formulationHealthRX +5
90
85
Clinical oversightHealthRX +4
87
83
Labs & monitoringHealthRX +30
82
52
FulfillmentHealthRX +25
86
61
Contract termsHealthRX +44
85
41
HealthRX · left barPauseRX · right bar

The numbers

MetricHealthRXPauseRX
WeighScore86.1/10068.5/100
GradeBC
Scorecard rank#8#147
Semaglutide$189/mo$199/mo
Tirzepatide$349/mo$249/mo (starting dose, compounded)
CoverageNot publicly listedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesInjection only
HealthRX

Graded #8 · B

Strengths

  • LegitScript-certified (#50087439) — a genuine, verifiable trust signal
  • Physician-supervised intake with licensed providers
  • Both molecules plus a rare oral GLP tablet option
  • Transparent flat monthly pricing, no insurance required

Where it loses points

  • Compounded semaglutide/tirzepatide is not FDA-approved
  • Some tiers are company-stated and the public site is thin
  • Brand Ozempic is a steep pass-through (~$1,299)
  • State count is not publicly listed
PauseRX

Graded #147 · C

Strengths

  • Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
  • Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
  • Publishes the FDA compounded-medication disclaimer
  • Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
  • Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation

Where it loses points

  • States served not listed — site claims nationwide, but you must contact support to confirm availability
  • Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
  • No named medical director (Beluga Health is the network, not a named MD)
  • LegitScript certification number not shown — badge only, so no direct lookup
  • Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard